X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1041) 1041
Publication (91) 91
Book Chapter (5) 5
Book Review (3) 3
Book / eBook (2) 2
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (648) 648
humans (566) 566
dipeptides - pharmacokinetics (428) 428
male (402) 402
pharmacology & pharmacy (390) 390
index medicus (358) 358
rats (316) 316
dipeptides - pharmacology (275) 275
female (173) 173
dipeptides - chemistry (171) 171
mice (162) 162
dipeptides - administration & dosage (161) 161
pharmacokinetics (133) 133
dipeptides - metabolism (128) 128
chemistry, medicinal (119) 119
administration, oral (117) 117
biochemistry & molecular biology (117) 117
peptide transporter 1 (116) 116
dipeptides - therapeutic use (112) 112
dose-response relationship, drug (111) 111
peptides (105) 105
adult (99) 99
kinetics (98) 98
rats, sprague-dawley (95) 95
absorption (85) 85
caco-2 cells (84) 84
structure-activity relationship (84) 84
biological availability (83) 83
beta-lactam antibiotics (80) 80
hydrogen-ion concentration (78) 78
biological transport (77) 77
rats, wistar (75) 75
dipeptides - chemical synthesis (73) 73
tissue distribution (73) 73
adamantane - analogs & derivatives (72) 72
carrier proteins - metabolism (70) 70
in vitro techniques (70) 70
rabbits (69) 69
middle aged (68) 68
chemistry, multidisciplinary (67) 67
intestinal absorption (67) 67
metabolism (66) 66
dipeptides (62) 62
permeability (62) 62
chromatography, high pressure liquid (61) 61
dipeptide (61) 61
dogs (60) 60
dipeptides - blood (59) 59
research (59) 59
time factors (59) 59
symporters - metabolism (58) 58
prodrugs - pharmacokinetics (57) 57
cell line, tumor (56) 56
molecular structure (55) 55
analysis (52) 52
dipeptides - adverse effects (52) 52
aged (50) 50
chemistry, organic (50) 50
drug design (50) 50
transport (50) 50
cell line (49) 49
drug stability (49) 49
in-vitro (49) 49
pharmacology/toxicology (49) 49
symporters (49) 49
intestinal mucosa - metabolism (48) 48
physiology (47) 47
diabetes mellitus, type 2 - drug therapy (45) 45
neurosciences (45) 45
symporters - genetics (45) 45
article (44) 44
proteins (44) 44
brush-border membrane (43) 43
chemistry (43) 43
drugs (43) 43
biological transport - drug effects (42) 42
cancer (42) 42
hydrolysis (42) 42
microvilli - metabolism (42) 42
expression (41) 41
half-life (41) 41
injections, intravenous (41) 41
intestinal absorption - drug effects (40) 40
therapy (40) 40
cells, cultured (39) 39
physiological aspects (39) 39
research article (39) 39
pharmacology (38) 38
prodrugs (38) 38
saxagliptin (38) 38
prodrugs - chemistry (37) 37
treatment outcome (37) 37
biochemistry, general (36) 36
intestine, small - metabolism (36) 36
oligopeptide transporter (36) 36
pept1 (36) 36
solubility (36) 36
adamantane - pharmacokinetics (35) 35
biomedicine (35) 35
drug interactions (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1021) 1021
Russian (15) 15
German (5) 5
Japanese (4) 4
French (2) 2
Spanish (2) 2
Chinese (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2010, Volume 12, Issue 8, pp. 648 - 658
Type 2 diabetes (T2DM) is a complex disease combining defects in insulin secretion and insulin action. New compounds have been developed for improving... 
DPP-4 inhibitor | Alogliptin | Sitagliptin | Linagliptin | Vildagliptin | Type 2 diabetes mellitus | Pharmacokinetics | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | linagliptin | RECEPTOR AGONISTS | saxagliptin | SINGLE-DOSE PHARMACOKINETICS | RENAL IMPAIRMENT | ORAL ANTIDIABETIC AGENTS | sitagliptin | vildagliptin | HEALTHY MALE-VOLUNTEERS | alogliptin | IV INHIBITOR | ENDOCRINOLOGY & METABOLISM | pharmacokinetics | type 2 diabetes mellitus | HEPATIC IMPAIRMENT | TYPE-2 DIABETES-MELLITUS | Dipeptides - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Half-Life | Male | Pyrazines - therapeutic use | Nitriles - pharmacokinetics | Pyrrolidines - therapeutic use | Drug Interactions | Adamantane - therapeutic use | Female | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Adamantane - pharmacokinetics | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Dipeptides - therapeutic use | Pyrrolidines - pharmacokinetics | Randomized Controlled Trials as Topic | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Pyrazines - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Type 2 diabetes | Physiological aspects | Glucose | Metabolites | Dextrose | Cytochrome P-450
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 07/2017, Volume 56, Issue 7, pp. 703 - 718
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2014, Volume 16, Issue 10, pp. 891 - 899
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 4/2011, Volume 50, Issue 4, pp. 253 - 265
Patients with type 2 diabetes mellitus often have impaired renal function or may have impaired hepatic function, which can pose significant safety and... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Research-and-development | Antihyperglycaemics, pharmacokinetics | Type-2-diabetes-mellitus | Diabetes-mellitus | Dipeptides, pharmacokinetics | Renal-impairment | Saxagliptin, pharmacokinetics | Haemodialysis | Liver-dysfunction | METFORMIN | THERAPY | CHRONIC LIVER-DISEASE | SAFETY | IMPROVES GLYCEMIC CONTROL | RISK | PHARMACOLOGY & PHARMACY | RANDOMIZED CONTROLLED-TRIAL | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Hepatic Insufficiency - urine | Dipeptides - pharmacokinetics | Humans | Middle Aged | Hypoglycemic Agents - analysis | Half-Life | Dipeptides - urine | Male | Metabolic Clearance Rate | Adamantane - urine | Adamantane - analysis | Adamantane - blood | Adult | Dipeptidyl-Peptidase IV Inhibitors - analysis | Female | Renal Insufficiency - blood | Hepatic Insufficiency - metabolism | Adamantane - pharmacokinetics | Adamantane - adverse effects | Adamantane - analogs & derivatives | Severity of Illness Index | Hypoglycemic Agents - pharmacokinetics | Dialysis Solutions - chemistry | Dipeptides - adverse effects | Dipeptides - analysis | Renal Insufficiency - metabolism | Renal Insufficiency - urine | Hepatic Insufficiency - blood | Kidney Failure, Chronic - metabolism | Kidney Failure, Chronic - therapy | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Kidney Failure, Chronic - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Dipeptides - blood | Renal Dialysis | Complications and side effects | Liver diseases | Physiological aspects | Dosage and administration | Research | Pharmacokinetics | Saxagliptin
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 1/2017, Volume 56, Issue 1, pp. 11 - 24
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2012, Volume 52, Issue 10, pp. 1494 - 1505
Dipeptidyl peptidase-4 (DPP-4) inhibition is a well- characterized treatment for type 2 diabetes mellitus (T2DM). The objective of this model-based... 
PK/PD | pharmacodynamics | DPP-4 | drug development | meta-analysis | Pharmacokinetics | diabetes | CLINICAL DRUG DEVELOPMENT | METFORMIN | RECEPTOR OCCUPANCY | TRIAL | IMPROVES GLYCEMIC CONTROL | IV INHIBITOR | DOUBLE-BLIND | EARLY DECISION-MAKING | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Triazoles - administration & dosage | Dipeptides - pharmacokinetics | Glycated Hemoglobin A - metabolism | Humans | Pyrazines - administration & dosage | Pyrrolidines - administration & dosage | Diabetes Mellitus, Type 2 - metabolism | Nitriles - pharmacokinetics | Nitriles - administration & dosage | Uracil - administration & dosage | Piperidines - pharmacokinetics | Triazoles - pharmacokinetics | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - pharmacokinetics | Adamantane - analogs & derivatives | Biomarkers - metabolism | Hypoglycemic Agents - therapeutic use | Piperidines - administration & dosage | Pyrrolidines - pharmacokinetics | Treatment Outcome | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptides - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Models, Biological | Pyrazines - pharmacokinetics | Diabetes Mellitus, Type 2 - drug therapy | Uracil - pharmacokinetics | Uracil - analogs & derivatives | Type 2 diabetes | Patient outcomes | Hypoglycemic agents | Dosage and administration | Models | Research | Drug therapy | Drug dosages
Journal Article
Journal Article
Journal Article
Xenobiotica, ISSN 0049-8254, 08/2018, Volume 48, Issue 8, pp. 809 - 817
1. The present study developed population pharmacokinetic models of arginine and glutamate in healthy Chinese volunteers. Two nonlinear mixed-effect models... 
Population pharmacokinetics | healthy Chinese volunteers | arginine | glutamate | NONMEM | DIETARY L-ARGININE | ULCERS | ACID | NITRIC-OXIDE SYNTHASE | RATS | SUPPLEMENTATION | GESTATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | Dipeptides - administration & dosage | Asian Continental Ancestry Group | Models, Biological | China | Dipeptides - pharmacokinetics | Humans | Adult | Female | Male
Journal Article